Molecular basis of the VHL hereditary cancer syndrome
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The interaction of pVHL with HIF-α is governed by the enzymatic hydroxylation of conserved proline residues that are located within highly conserved, peptidic, pVHL-binding domains within the HIF-α subunit”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Research works printed but not linked: 5
- Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
- Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
- Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
- Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
- Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).
Cited by
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
“The transcriptional activity of Hif-1 is thus repressed during normoxia (11).”
BackgroundInfluentialSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002; Safran and Kaelin, 2003), these results indicate that inhibiting SDH activity in cells results in decreased PHD activity. purified HA-pVHL protein and GFP-ODD/HA-pVHL complexes were detected by an anti-HA antibody…”
BackgroundReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
Lonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,600
Oxygen, oxidative stress, hypoxia, and heart failure
Giordano, F. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524408 · Cited by 1,496
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384
Self-citationCancer's Molecular Sweet Tooth and the Warburg Effect
Kim, J.-W., & Dang, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1501 · Cited by 1,215
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Appelhoff, R. J., Tian, Y.-M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., & Gleadle, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406026200 · Cited by 1,108
Pathways of apoptotic and non-apoptotic death in tumour cells
Okada, H., & Mak, T. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1412 · Cited by 1,044
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
“Inactivation of the VHL tumour suppressor gene is linked to the development of several different tumour types in humans, including hereditary and sporadic clear cell carcinoma of the kidne”
BackgroundThe genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Wang, Y., Wan, C., Deng, L., Liu, X., Cao, X., Gilbert, S. R., Bouxsein, M. L., Faugere, M.-C., Guldberg, R. E., Gerstenfeld, L. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31581 · Cited by 733
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 621
Chi, J.-T., Wang, Z., Nuyten, D. S. A., Rodriguez, E. H., Schaner, M. E., Salim, A., Wang, Y., Kristensen, G. B., Helland, Å., Børresen-Dale, A.-L., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030047 · Cited by 619
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
“Enzymatic hydroxylation of conserved prolyl residues within these proteins by members of the egg-laying-defective nine (EGLN) family is required for their recognition by pVHL (Kaelin 2002).”
BackgroundInfluentialSelf-citationZimna, A., & Kurpisz, M. (2015) · BioMed Research International · doi:10.1155/2015/549412 · Cited by 604
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596
Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis
Robey, R. B., & Hay, N. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.010 · Cited by 540
Mitohormesis: Promoting Health and Lifespan by Increased Levels of Reactive Oxygen Species (ROS)
Ristow, M., & Schmeisser, K. (2014) · Dose-Response · doi:10.2203/dose-response.13-035.ristow · Cited by 534
Lactate in the tumour microenvironment: From immune modulation to therapy
Wang, Z.-H., Peng, W.-B., Zhang, P., Yang, X.-P., & Zhou, Q. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103627 · Cited by 528
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528
Self-citationLee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M. S., Sajan, M. P., Farese, R. V., Freeman, R. S., Carter, B. D., Kaelin, W. G., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.015 · Cited by 527
Self-citationOrlicky, S., Tang, X., Willems, A., Tyers, M., & Sicheri, F. (2003) · Cell · doi:10.1016/s0092-8674(03)00034-5 · Cited by 509
Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., Conaway, J. W., & Nakayama, K. I. (2004) · Genes & Development · doi:10.1101/gad.1252404 · Cited by 477
Proline hydroxylation and gene expression
Kaelin, W. G. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133142 · Cited by 468
Self-citationA hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin
Willems, A. R., Schwab, M., & Tyers, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.027 · Cited by 464
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 458
A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
“gene, whose product is a known regulator of the activity of the HIF pathway [”
BackgroundRole of mitochondrial reactive oxygen species in homeostasis regulation
Zhang, B., Pan, C., Feng, C., Yan, C., Yu, Y., Chen, Z., Guo, C., & Wang, X. (2022) · Redox Report · doi:10.1080/13510002.2022.2046423 · Cited by 395
The VHL/HIF axis in clear cell renal carcinoma
Shen, C., & Kaelin, W. G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.001 · Cited by 388
Self-citationRankin, E. B., Tomaszewski, J. E., & Haase, V. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3241 · Cited by 363
GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360
Structural integration in hypoxia-inducible factors
Wu, D., Potluri, N., Lu, J., Kim, Y., & Rastinejad, F. (2015) · Nature · doi:10.1038/nature14883 · Cited by 346
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., & Krek, W. (2003) · Nature Cell Biology · doi:10.1038/ncb899 · Cited by 339
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Self-citationKaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Self-citationBiology of hypoxia-inducible factor-2α in development and disease
Patel, S. A., & Simon, M. C. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.17 · Cited by 327
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 306
Genetic analysis of von Hippel-Lindau disease
Nordstrom-O'Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., van Brussel, A., Voest, E. E., & Giles, R. H. (2010) · Human Mutation · doi:10.1002/humu.21219 · Cited by 311
Jensen, R. L. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9827-2 · Cited by 287
HIF-1 and HIF-2: working alone or together in hypoxia?
Ratcliffe, P. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31750 · Cited by 283
Welsh, S. J., Williams, R. R., Kirkpatrick, L., Paine-Murrieta, G. D., & Powis, G. (2004) · PubMed · Cited by 280
Kusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.346 · Cited by 276
Regulation of Angiogenesis by Hypoxia and Hypoxia‐Inducible Factors
Hickey, M. M., & Simon, M. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76007-0 · Cited by 271
Hu, C.-J., Iyer, S., Sataur, A., Covello, K. L., Chodosh, L. A., & Simon, M. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.9.3514-3526.2006 · Cited by 266
The adverse effects of maternal smoking on the human placenta: A review
Zdravkovic, T., Genbacev, O., McMaster, M. T., & Fisher, S. J. (2005) · Placenta · doi:10.1016/j.placenta.2005.02.003 · Cited by 262
Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor
Esteban, M. A., Tran, M. G. B., Harten, S. K., Hill, P., Castellanos, M. C., Chandra, A., Raval, R., O'Brien, T. S., & Maxwell, P. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2670 · Cited by 262
“von Hippel-Lindau (VHL) disease is an autosomal dominant multitumor syndrome, which includes anf70% lifetime risk of clear cell renal cell carcinoma (CCRCC), multiple visceral cysts (affecting the kidney and also other organs), hemangioblastomas of the central nervous system and retina, and pheochromocytomas (1).”
BackgroundHIF activation by pH-dependent nucleolar sequestration of VHL
Mekhail, K., Gunaratnam, L., Bonicalzi, M.-E., & Lee, S. (2004) · Nature Cell Biology · doi:10.1038/ncb1144 · Cited by 262
Folding and Quality Control of the VHL Tumor Suppressor Proceed through Distinct Chaperone Pathways
McClellan, A. J., Scott, M. D., & Frydman, J. (2005) · Cell · doi:10.1016/j.cell.2005.03.024 · Cited by 259
Couvelard, A., O'Toole, D., Turley, H., Leek, R., Sauvanet, A., Degott, C., Ruszniewski, P., Belghiti, J., Harris, A. L., Gatter, K., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602245 · Cited by 257
VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail
Evans, A. J., Russell, R. C., Roche, O., Burry, T. N., Fish, J. E., Chow, V. W. K., Kim, W. Y., Saravanan, A., Maynard, M. A., Gervais, M. L., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00892-06 · Cited by 248
Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.233.3.3 · Cited by 240
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Roe, J.-S., Kim, H., Lee, S.-M., Kim, S.-T., Cho, E.-J., & Youn, H.-D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.006 · Cited by 237
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235
“…alpha subunit genes (HIF1a, HIF2a, or HIF3a) and three HIFb genes (also called the aryl hydrocarbon receptor nuclear translocator (ARNT)) (Semenza, 2003). pVHL binds directly to HIFa subunits and orchestrates their polyubiquitination, leading to their destruction by the proteasome (Kaelin, 2002).”
BackgroundSelf-citationPost‐transcriptional regulation in cancer
Audic, Y., & Hartley, R. S. (2004) · Biology of the Cell · doi:10.1016/j.biolcel.2004.05.002 · Cited by 234
Jung, M., Mollenkopf, H., Grimm, C., Wagner, I., Albrecht, M., Waller, T., Pilarsky, C., Johannsen, M., Stephan, C., Lehrach, H., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00705.x · Cited by 229
Signaling pathways in renal cell carcinoma
Banumathy, G., & Cairns, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.13247 · Cited by 221
Olenyuk, B. Z., Zhang, G.-J., Klco, J. M., Nickols, N. G., Kaelin, W. G., & Dervan, P. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407617101 · Cited by 219
Self-citation(2015) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-62702-5.00010-x · Cited by 211
Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 216
HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels
Masson, N., & Ratcliffe, P. J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00655 · Cited by 215
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
Kaelin, W. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.165 · Cited by 214
Self-citationSearching for the hereditary causes of renal-cell carcinoma
Pavlovich, C. P., & Schmidt, L. S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1364 · Cited by 209
Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis
Basten, S. G., & Giles, R. H. (2013) · Cilia · doi:10.1186/2046-2530-2-6 · Cited by 208
The ubiquitin proteasome system in neuropathology
Lehman, N. L. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0560-x · Cited by 207
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background
Fishbein, L., & Nathanson, K. L. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.01.009 · Cited by 208
Metabolic reprogramming in renal cancer: Events of a metabolic disease
Chakraborty, S., Balan, M., Sabarwal, A., Choueiri, T. K., & Pal, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188559 · Cited by 204
The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities
Elias, R., Zhang, Q., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 205
Moore, L. E., Nickerson, M. L., Brennan, P., Toro, J. R., Jaeger, E., Rinsky, J., Han, S. S., Zaridze, D., Matveev, V., Janout, V., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002312 · Cited by 199
VHL protein‐interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF‐1α
Li, Z., Wang, D., Messing, E. M., & Wu, G. (2005) · EMBO reports · doi:10.1038/sj.embor.7400377 · Cited by 196
Yan, Q., Bartz, S., Mao, M., Li, L., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01514-06 · Cited by 193
Self-citationRegulation of endocytosis via the oxygen-sensing pathway
Wang, Y., Roche, O., Yan, M. S., Finak, G., Evans, A. J., Metcalf, J. L., Hast, B. E., Hanna, S. C., Wondergem, B., Furge, K. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1922 · Cited by 192
HIFs, angiogenesis, and cancer
Yang, Y., Sun, M., Wang, L., & Jiao, B. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24438 · Cited by 191
Will mTOR inhibitors make it as cancer drugs?
Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00275-7 · Cited by 190
Petrella, B. L., Lohi, J., & Brinckerhoff, C. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208305 · Cited by 188
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 188
The ubiquitin‐proteasome pathway
Roos‐Mattjus, P., & Sistonen, L. (2004) · Annals of Medicine · doi:10.1080/07853890310016324 · Cited by 185
Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment
Ro, C., Chai, W., Yu, V. E., & Yu, R. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10295 · Cited by 184
HIFs and tumors—causes and consequences
Höpfl, G., Ogunshola, O., & Gassmann, M. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00538.2003 · Cited by 185
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer
Li, G., Ci, W., Karmakar, S., Chen, K., Dhar, R., Fan, Z., Guo, Z., Zhang, J., Ke, Y., Wang, L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.007 · Cited by 177
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
Yang, H., Minamishima, Y. A., Yan, Q., Schlisio, S., Ebert, B. L., Zhang, X., Zhang, L., Kim, W. Y., Olumi, A. F., & Kaelin, W. G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.09.010 · Cited by 179
Self-citationThe hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation
Bedogni, B., Welford, S. M., Cassarino, D. S., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.005 · Cited by 179
Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Gu, Y.-F., Cohn, S., Christie, A., McKenzie, T., Wolff, N., Do, Q. N., Madhuranthakam, A. J., Pedrosa, I., Wang, T., Dey, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0292 · Cited by 176
Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors
Downie, B. R., Sánchez, A., Knötgen, H., Contreras-Jurado, C., Gymnopoulos, M., Weber, C., Stühmer, W., & Pardo, L. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801830200 · Cited by 175
The von Hippel–Lindau tumor suppressor protein: new insights into oxygen sensing and cancer
Kim, W., & Kaelin, W. G. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00010-2 · Cited by 175
Self-citationLoss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer
Chen, K., Zhang, J., Guo, Z., Ma, Q., Xu, Z., Zhou, Y., Xu, Z., Li, Z., Liu, Y., Ye, X., et al. (2016) · Cell Research · doi:10.1038/cr.2015.150 · Cited by 174
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 161
Self-citationAlterations in VHL as potential biomarkers in renal-cell carcinoma
Gossage, L., & Eisen, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 167
Maxwell, P. H. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.03.001 · Cited by 167
Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors
Chen, L., Endler, A., & Shibasaki, F. (2009) · Experimental and Molecular Medicine · doi:10.3858/emm.2009.41.12.103 · Cited by 164
Renal cell carcinoma: a review of biology and pathophysiology
Nabi, S., Kessler, E. R., Bernard, B., Flaig, T. W., & Lam, E. T. (2018) · F1000Research · doi:10.12688/f1000research.13179.1 · Cited by 161
Philip, B., Ito, K., Moreno-Sanchez, R., & Ralph, S. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt209 · Cited by 161
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
Self-citation
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Nature Reviews Cancer
- Published
- 2002-09
- Volume
- 2
- Issue
- 9
- Pages
- 673-682
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2093776019
- Semantic Scholar
- 6b13bcf0623256d5dceb071144a84d45b84f9a99
- Cited by
- 865
- References
- 146
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
- MeSH terms
- Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.